![Scott Biller](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: - $ in data 30/06/2026
Scott Biller is currently Director at OMass Therapeutics Ltd. since 2022, Independent Director at Foghorn Therapeutics, Inc. since 2020, Director at Remix Therapeutics, Inc. since 2020, and Director at Rome Therapeutics, Inc. since 2021.
Formerly, Dr. Biller was Chief Scientific Officer at Agios Pharmaceuticals, Inc. from 2010 to 2019, Vice President & Head-Global Discovery Chemistry at Novartis Institutes for Biomedical Research, Inc. from 2003 to 2010, and VP-Pharmaceutical Candidate Optimization at Bristol-Myers Squibb Pharmaceutical Research Institute from 2001 to 2003.
Education includes an undergraduate degree from Massachusetts Institute of Technology in 1976 and a doctorate from California Institute of Technology in 1981.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 24/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Direttore/Membro del Consiglio | 09/01/2020 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Direttore/Membro del Consiglio | 01/06/2020 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Direttore/Membro del Consiglio | 01/02/2021 |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Direttore/Membro del Consiglio | 01/01/2022 |
| Società | Posizione | Fine |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 31/12/2019 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/09/2010 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/07/2003 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Commercial Services |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
